Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Capsaicin offers pain relief in knee OA patients

14 Aug 2019

The high‐purity synthetic trans‐capsaicin CNTX‐4975 provides dose-dependent reduction in knee osteoarthritis (OA)-associated pain, as shown in the results of a phase II study.

The study randomized 172 patients aged 45–80 years to receive a single intra-articular injection of placebo (n=69), or CNTX‐4975 at 0.5 mg (n=33) or 1.0 mg (n=70). All patients had radiographic evidence of knee OA (Kellgren/Lawrence [K/L] grade 2–4).

Researchers evaluated efficacy in terms of the area under the curve (AUC) for change from baseline in daily Western Ontario and McMaster Universities Osteoarthritis Index pain with walking score (range 0–10; 0=none and 10=extreme) through week 12. They also performed a similar AUC analysis of outcomes in patients receiving CNTX‐4975 0.5 mg, as well as evaluations extending to 24 weeks.

Week-12 results revealed greater reductions in the AUC for the pain score with both CNTX‐4975 doses than with placebo (0.5 mg: least squares mean difference [LSMD], −0.79, 90 percent CI, −1.5 to −0.06; p=0.0740; 1.0 mg: LSMD, −1.6, −2.2 to −1.0; p<0.0001).

Significant improvements were maintained at week 24 in the 1.0-mg dose group (vs placebo: LSMD, −1.4; p=0.0002) but not in the group that received the 0.5 mg dose (LSMD, −0.6, −1.3 to 0.15; p=0.19).

Treatment‐emergent adverse events were similar, occurring in 30 percent of patients in the placebo group, 47 percent in the 0.5-mg dose group and 30 percent in the 1.0-mg dose group. The events were generally mild (19 percent, 29 percent and 20 percent) or moderate (11 percent, 18 percent and 10 percent) in severity. There were no deaths reported.

The present data support further clinical development of CNTX‐4975.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.